December 17, 2012

HELIX BIOPHARMA ANNOUNCES DIRECTOR RESIGNATIONS (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing
drug candidates for the prevention and treatment of cancer, today announced that each of Jack A. Kay and
W. Thomas Hodgson had voluntarily resigned from Helix’s board of directors with effect from December 14,
2012.